RESEARCH > Urology Care Foundation Research Awards > Researcher Profiles

Researcher Profiles

To find out more on these exceptional individuals and their research projects please click on their name below.

2013 – 2015 Research Scholars 2014 – 2015 Research Scholars

Jennifer Bishop, PhD
Saunders Ching, PhD
Arindam Ghosh, PhD
Johanna Hannan, PhD
Mahendra Kashyap, PhD
Dirk Lange, PhD

Philip Abbosh, MD, PhD
Judy Choi, MD
Catherine Gordon, PhD
Chinedu Mmeje, MD

2014 – 2016 Research Scholars  

Irina Debnath, PhD
Sonia Fargue, MD, PhD
Chunming Guo, PhD
Andrew Hau, PhD
Zhu Juan (Sue) Li, PhD
Shu Lin, PhD
Tomasz Owczarek, PhD
Bharathi Rajaganapathy, PhD
Sungyong You, PhD


2013 – 2015 Research Scholars

Jennifer Bishop, PhD

Jennifer Bishop, PhD

Project Title: Beyond the AR: Characterizing Cell Plasticity in Prostate Cancer Resistant to 2nd Generation Anti-Androgens

Institution: University of British Columbia

Mentor: Amina Zoubeidi, PhD

Sponsor: Urology Care Foundation

One in seven men in North America will be diagnosed with prostate cancer in their lifetime, and many will undergo therapies targeting androgens, which promote tumor growth, in hopes of controlling their disease. Inevitably, however, these patients develop lethal castration resistant prostate cancer (CRPC), a disease which is especially drug resistant. Dr. Bishop will study the responses of CRPC tumor cells to novel anti-prostate cancer therapies in an attempt to understand why they become drug resistant and to identify molecular changes in the cells that may be targeted to improve CRPC treatments. Her work suggests that a more primitive cancer stem cell may contribute to drug resistance by giving rise to various types of aggressive tumor cells during disease progression. Ultimately, Dr. Bishop aims to target these diverse CRPC cells with new drugs that will hopefully improve survival of prostate cancer patients.

Urology Care Foundation

[ return to top ]
Saunders Ching, PhD

Saunders Ching, PhD

Project Title: Sprouty Genes are Required for Mammalian Genital Development

Institution: University of California, San Francisco

Mentor: Laurence Baskin, MD

Sponsor: Amgen, Inc.

Hypospadias is a birth defect that affects the fetal development of the penis. This results in defective formation of the urethra and abnormal placement of the urethral opening on the underside of the penis. Consequently, it can cause severe psychosexual problems and voiding abnormalities despite the best efforts at surgical reconstruction. It is one of the most common birth defects, affecting approximately 1 in every 250-300 live male births, but the genetic causes of hypospadias are not clearly understood.

The goal of Dr. Ching's research is to identify the genes and molecular pathways that regulate genital development. By using genetic knockout mice, he has characterized an animal model of hypospadias that can be used to identify the critical genes involved in genital development. The knowledge gained from these studies may lead to improved treatments, better prenatal diagnosis and prevention of hypospadias in human patients.

Dr. Ching recently published an article in Developmental Biology on his work supported by the Urology Care Foundation and Amgen®. Read more about the article entitled, "Coordinated activity of Spry1 and Spry2 is required for normal development of the external genitalia."

Amgen, Inc.

[ return to top ]
Arindam Ghosh, PhD

Arindam Ghosh, PhD

Project Title: mTOR Regulation of Renal Cancer

Institution: University of Alabama at Birmingham

Mentor: Sunil Sudarshan, MD

Sponsor: AUA Southeastern Section Research Scholar Fund

Kidney cancer is one of the 10 most common types of cancer in men and women, affecting over 300,000 people in the United States. The mammalian target of rapamycin (mTOR) has emerged as a biologically significant pathway in renal cancers, as several studies have reported an increase in mTOR signaling in renal cancers in comparison to normal renal tissue. Recent deep sequencing efforts of renal tumor samples have identified mutations in mTOR. Dr. Ghosh aims to characterize the functional significance of these point mutations with regard to their tumorigenic potential and define the mechanisms by which mTOR is activated in renal tumors.

AUA Southeastern Section Research Scholar Fund

[ return to top ]
Johanna Hannan, PhD

Johanna Hannan, PhD

Project Title: The Role of STIM/Orai Calcium Signaling in Peripheral Cavernous Nerve Injury

Institution: Johns Hopkins Medical Institutes

Mentors: Arthur L. Burnett, MD, MBA, and Trinity J. Bivalacqua, MD, PhD

Sponsor: AUA Mid-Atlantic Section Research Scholar Fund

Prostate cancer is currently the most commonly diagnosed cancer in the United States and remains a significant health problem. The mortality rates of this disease are much lower due to early diagnosis and radical prostatectomy for surgical management of clinically localized prostate cancer. Advances in the field of neurourology have focused on the development and implementation of strategies for preserving the functional integrity of the cavernous nerves and the penile vasculature following radical prostatectomy in order to improve postoperative erectile function outcomes.

Nonetheless, common side effects from the treatment of the diseases such as erectile and urinary dysfunction still exist. Dr. Hannan's research will focus on identifying a novel signaling pathway (STIM/Orai) involved in cavernous nerve axonal regeneration after injury with the goal of perseveration of neuroregulatory control of penile erection. The findings of her study may be used to develop new disease-specific pharmacotherapies for the treatment of post-prostatectomy erectile dysfunction as well as other peripheral nervous system neuropathic conditions.

AUA Mid-Atlantic Section Research Scholar Fund

[ return to top ]

2013 Urology Care Foundation Research Scholar Award Funded by the Allergan Foundation Scholar

Mahendra Kashyap, PhD

Mahendra Kashyap, PhD

Project Title: Characterization of Neurogenic and Myogenic Changes Induced by Overexpression of BDNF in Bladder

Institution: University of Pittsburgh

Mentors: Naoki Yoshimure, PhD; Pradeep Tyagi, PhD; and William C. Degroat, PhD

Sponsor: The Allergan Foundation

Understanding of the causes underlying OAB remain uncertain, and it is generally defined by the symptom of urgency, which is often associated with detrusor overactivity (DO) seen during the storage phase of micturition. Dr. Kashyap's research project is focused on elucidating the role played by abnormal expression of brain-derived neurotrophic factor (BDNF) in bladder functions and the phenotypic changes in sympathetic nerves brought about by BDNF that have implications in the OAB symptoms. These studies might advance knowledge on the biological basis of OAB and perhaps translate the knowledge to clinical use.

Dr. Kashyap will attend the 2014 winter meeting of “Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction” (SUFU) to be held in Miami, Florida, to present his abstract entitled “Constitutively Active Hcn Channels Facilitate Relaxation of Spontaneously Contracting Rat Bladder”.

The Allergan Foundation

[ return to top ]

2013 Joseph Segura, MD Scholarship in Endourology and Stone Management

Dirk Lange, PhD

Dirk Lange, PhD

Project Title: Understanding the Molecular Mechanisms Triggering Stent-induced Ureteral Aperistalsis

Institution: University of British Columbia

Mentors: S. Larry Goldenberg, MD; Ben H. Chew, MD; and Ralph Buttyan, PhD

Sponsor: Boston Scientific Corporation, The Endourological Society, and the "Friends of Joe"

When a person has a kidney stone, small plastic straw-like tubes called "stents" can be inserted past the blocking stone to help urine flow freely from the kidney into the bladder. While assisting overall urine flow, stents are known to interfere with the normal functioning of the ureter, the tube that connects the kidneys to the bladder and drives urine flow. This results in severe discomfort to the patient and, if not addressed, can result in damage to the kidneys. The purpose of Dr. Lange's study is to better understand the mechanisms that result in the disrupted functioning of the stented ureter, as it can lead to the development of a drug to counteract these effects and improve the treatment available to the millions of North Americans suffering from kidney stone disease.

Boston Scientific Corporation The Endourological Society Friends of Joe
[ return to top ]

2014 – 2015 Research Scholars

Philip Abbosh, MD, PhD

Philip Abbosh, MD, PhD

Project Title: The Role of PBRM1 Mutation in Renal Cell Carcinoma

Institution: Fox Chase Cancer Center

Mentor: Paul Cairns, PhD and Robert Uzzo, MD

Sponsor: Kidney Cancer Association

Tremendous insights into the molecular underpinnings of kidney cancer were gained upon the publication of the kidney cancer genome. These studies have revealed that clear cell renal cell carcinoma, the most common form of kidney cancer, is associated with multiple recurrent mutations in a group of proteins which modify histones (the scaffold onto which DNA wraps and is packaged to form chromatin). This gives rise to the idea that kidney cancer might be a disease of epigenetic mutations (changes to chromatin which do not modify DNA sequence). Such mutations are potentially reversible by activating or inhibiting the enzymes which catalyze their placement or removal. The most commonly mutated chromatin-modifying gene in kidney cancer, PBRM1, encodes a component of the SWI-SNF complex, which physically moves histones out of the way during transcription, allowing DNA to accessed by gene-activating machinery. The role of the SWI-SNF complex in activating gene expression and identifying changes that occur after loss of PBRM1 will be examined. In particular, the interaction of SWI-SNF with other chromatin-modifying complexes will be explored. Interestingly, components of the SWI-SNF complex are mutated in several other malignancies, and so elucidation of the impact of these mutations in kidney cancer might provide insight into the pathogenesis and treatment of other diseases.

Kidney Cancer Association

[ return to top ]

2014 Urology Care Foundation Research Scholar Award Funded by the Allergan Foundation

Judy Choi, MD

Judy Choi, MD

Project Title: Chronic Stress Affects the Micturition Pathway via the Peripheral Corticotropin-releasing Factor (CRF) Pathway

Institution: University of California Los Angeles

Mentor: Shlomo Raz, MD and Muriel Larauche, PhD

Sponsor: The Allergan Foundation

Interstitial cystitis/painful bladder syndrome (IC/PBS) remains a poorly understood phenomenon in which patients often report increased urinary frequency and pain with bladder filling, without any obvious etiology. It can thus be difficult to diagnose and treat. Physical and emotional stress appears to play a role in the exacerbation and the development of IC/PBS. Dr Choi's research centers around the theory that a psychological or physical stressor leads to neurogenic inflammation of the bladder, which then results in altered pain sensations. Utilizing a water avoidance stress (WAS) rodent model to mimic chronic adult stress, her study aims to evaluate the role of the peripheral corticotropin-releasting factor (CRF) system in modulating bladder motor and sensory function via mast cell activation. There are two main aims: 1) Describe the expression of bladder CRF ligands and receptors and mast cell activation in animals subjected to WAS and compare it to controls, and 2) Asses the role of CRF and its receptors in the development of stress-induced bladder hyperalgesia and voiding dysfunction.

The Allergan Foundation

[ return to top ]
Catherine Gordon, PhD

Catherine Gordon, PhD

Project Title: Understanding the Role of NuSAP in Prostate Cancer Progression to Improve Patient Management

Institution: Stanford University

Mentor: James Brooks, MD

Sponsor: Urology Care Foundation

Nucleolar and spindle-associated protein (NuSAP) is a protein turned on in more aggressive forms of prostate cancer. In Dr. Gordon’s efforts to determine the biological role of NuSAP in prostate cancer progression she has discovered that NuSAP increases invasion of prostate cancer cells grown in the laboratory and leads to an activation of genes involved in cellular movement, processes important in allowing cancer cells to spread (metastasize). Dr. Gordon now plans to extend these studies by determining whether NuSAP makes human cancer cells more aggressive when grown in mice, determining how NuSAP makes cancers more aggressive by testing how NuSAP turns genes on and off, and testing whether NuSAP affects the response of prostate cancer cells to chemotherapy. This research will provide insights into the inner workings of aggressive prostate cancer cells and may lead to new ways to predict and treat deadly forms of prostate cancer.

Urology Care Foundation

[ return to top ]
Chinedu Mmeje, MD

Chinedu Mmeje, MD

Project Title: Assessing Th2 Immune Response in Patients with Non-muscle Invasive Bladder Cancer

Institution: University of Texas M.D. Anderson Cancer Center

Mentor: Ashish Kamat, MD

Sponsor: AUA South Central Section Research Scholar Fund

Dr. Mmeje's project involves evaluating the tumor immune response of patients with non-muscle invasive bladder cancer, and comparing their immune response to that of patients with muscle invasive disease. Chemical staining for immune markers (Th2 vs. Th1) of bladder biopsy tissue at the time of diagnosis will be performed to determine the tumor immune response. The project will attempt to determine whether there is a difference in the tumor response between the two disease stages, as well as during the progression to muscle invasive bladder cancer. This information would be used to direct projects to further delineate the natural differences between the two stages, which could lead to the development of therapeutic agents for bladder cancer. Dr. Mmeje will also validate a diagnostic technique to predict the effectiveness of treatment for non-muscle invasive bladder cancer.

AUA South Central Section Research Scholar Fund

[ return to top ]

2014 – 2016 Research Scholars

Irina Debnath, PhD

Irina Debnath, PhD

Project Title: Identification and Characterization of the MrpJ Virulence Gene Network in Uropathogenic Proteus mirabilis

Institution: New York University School of Medicine

Mentor: Melanie Pearson, PhD

Sponsor: AUA New York Section Research Scholar Fund

Proteus mirabilis is a major cause of catheter-associated urinary tract infections (UTIs), a type of complicated UTIs that affect a large portion of the aging population in long-term care facilities and hospitalized patients with indwelling urinary catheters, incurring a steep healthcare cost and heavy public health burden worldwide. In addition to severe bladder and kidney infections, this bacterium manifests an alarmingly high percentage of antibiotic resistance and causes urolithiasis or kidney stones, further complicating the disease progression and treatment. Two critical aspects of P. mirabilis virulence are hair-like surface appendages (fimbriae / pili), which mediate attachment to the host's urinary tract, and tail-like flagella, which mediate motility. Dr. Debnath's research is focused on major P. mirabilis gene regulator MrpJ, which modulates the inverse temporal regulation of these two virulence processes during UTI and whose absence renders these bacteria highly attenuated in pathogenesis. Her data suggest that MrpJ regulates a number of other critical virulence effectors and Dr. Debnath hypothesizes that MrpJ is orchestrating an intricate virulence gene network during UTI. Her study will determine the various virulence genes in this network directly regulated by MrpJ, the molecular mechanism of this regulation, and how MrpJ and a subset of MrpJ-regulated genes modulate the host's immune defense to establish disease in the urinary tract, thus defining novel pathogenic targets for future therapeutics.

AUA New York Section Research Scholar Fund

[ return to top ]
Sonia Fargue, MD, PhD

Sonia Fargue, MD, PhD

Project Title: Metabolism Associated with Hyperoxaluria and Calcium Oxalate Stone Disease

Institution: University of Alabama at Birmingham

Mentor: Ross Holmes, PhD and Dean Assimos, MD

Sponsor: AUA Southeastern Section Research Scholar Fund

Kidney stones have been reported to affect at least 5% of Western populations. Of these, calcium oxalate stones are the most common. The primary hyperoxalurias are severe inherited diseases, which cause recurring calcium oxalate stones, may lead to renal failure and necessitate transplantation. Three different forms of primary hyperoxalurias have been identified, all three involving enzyme of the metabolism of oxalate and glyoxylate, a precursor of oxalate. The goal of Dr. Fargue's proposed research is to elucidate some of the mechanisms of the glyoxylate metabolism, using cell models of primary hyperoxaluria. The insights that will be gained in this way will not only help design treatments for patients with primary hyperoxaluria, but will also shed light on pathways that are involved in the more common forms of calcium oxalate kidney stones.

AUA Southeastern Section Research Scholar Fund

[ return to top ]
Chunming Guo, PhD

Chunming Guo, PhD

Project Title: A Mouse Model for Human Urinary Incontinence

Institution: Children's Hospital Boston

Mentor: Sean Xue Li, PhD

Sponsor: AUA New England Section Research Scholar Fund

Human Urofacial Syndrome (UFS) (aka, Ochoa syndrome), a rare autosomal recessive disease with dysfunctional urination, including urinary incontinence, frequency and urgency. Dr. Guo has successfully generated a mouse Hpse2 mutant line that models UFS. This is the first and the only mouse model of UFS, which enables him to study specific aspects of molecular and cellular basis of complex urological problems including urinary incontinence. In this project, Dr. Guo is investigating neuronal and muscular basis of Hpse2 mutant defects in lower urinary tracts.

AUA New England Section Research Scholar Fund

[ return to top ]
Andrew Hau, PhD

Andrew Hau, PhD

Project Title: uPAR and mTORC2: Coupled Targets for Therapeutics Development in Bladder Cancer

Institution: University of California San Diego

Mentor: Donna Hansel, MD, PhD

Sponsor: Frank and Marion Hinman Urology Research Fund

Bladder cancer represents one of the deadliest cancers globally and will account for over 15,000 deaths in the United States in 2013. For patients with invasive bladder cancer, the gold standard of treatment involves radical cystectomy, which is initially effective in decreasing morbidity. However, the high recurrence and distant metastasis within the first several years post-surgery necessitates new treatment options and a better understanding of the molecular mechanisms underlying this disease. Presently, Dr. Hau and his research team have identified two powerful pro-invasion candidates that have increased expression in high-grade, invasive bladder cancer and our research suggests that combined inhibition of these factors could represent a new therapeutic option for the management of bladder cancer.

[ return to top ]
Zhu Juan (Sue) Li, PhD

Zhu Juan (Sue) Li, PhD

Project Title: Targeting Cancer Stem Cells in Castration-resistant Prostate Cancer

Institution: Princess Margaret Hospital – Ontario

Mentor: Anthony Michael Joshua, MBBS, PhD and Bradley Wouters, PhD

Sponsor: AUA Northeastern Section Research Scholar Fund

Treatment options for men with castration-resistant prostate cancer (CRPC) remains a significant clinical challenge. Current regimens include androgen receptor-antagonists (such as enzalutamide (ENZ)), which are known to improve the overall survival of men post chemotherapy but unfortunately all responders will eventually develop resistance. There is increasing evidence that tumor recurrence is driven by a rare population of cells termed "cancer stem cells" (CSC) which are responsible for tumor initiation, maintenance and resistance to therapy. Therefore, targeting prostate CSCs (PCSC) and properties involved in their drug-resistance, such as autophagy could become novel therapeutic strategies to treat men with CRPC. Dr. Li hypothesizes that therapeutic resistance to ENZ functionally selects for PCSCs and that PCSCs utilizes autophagy as a survival strategy to overcome anti-cancer treatments such as ENZ. In this research study she will functionally characterize ENZ-resistant cells, determine the role of autophagy for PCSC cell survival and devise therapeutic strategies to target cancer stem cells in CRPC. Molecular and functional characterization of ENZ-resistant PCSCs from this study will guide therapeutic developments and potentially identify biomarkers for men with CRPC.

AUA Northeastern Section Research Scholar Fund

[ return to top ]
Shu Lin, PhD

Shu Lin, PhD

Project Title: Determining the Role of Epithelial-mesenchymal Transition in Prostate Cancer and Stem Cells During Castration-resistant Cancer Progression

Institution: University of California Los Angeles

Mentor: Robert Reiter, MD

Sponsor: Robert J. Krane, MD Urology Research Scholar Fund

Patients with advanced prostate cancer are often treated first with anti-androgen therapies, but will invariably develop deadly castration resistant prostate cancer (CRPC) without clear mechanism. Epithelial to mesenchymal transition (EMT) has been suggested as a critical pathway utilized by cancer stem cells (or by epithelial tumor cells to confer stem cell properties) to survive after androgen ablation and that this adaptive response underlies the development of castration resistance. However, there is a lack of direct evidence for the role of EMT in prostate stem cells, and little is known about the pivotal pathways mediating EMT in prostate cancer. In this study, Dr. Lin proposes to clarify the relationship of N-cadherin, Zeb-1 and other transcriptional activator of EMT to prostate stem cell behavior and prostate cancer invasion, metastasis and CRPC progression. She will also determine the role of AR in these processes. Her proposed research will likely reveal an important role of EMT in prostate cancer and stem cells, and provide useful information of EMT-related biomarkers for preventing and developing efficient therapeutics to combat the treatment resistance to next-generation AR antagonists.

[ return to top ]
Tomasz Owczarek, PhD

Tomasz Owczarek, PhD

Project Title: Cell of Origin of Bladder Cancer

Institution: Columbia University Medical Center

Mentor: Cory Abate-Shen, PhD

Sponsor: Dornier MedTech

Dr. Owczarek's research proposal is focused on understanding how the various cells in the bladder give rise to bladder cancer. Normal bladder epithelium consists of three different cell types that differ significantly from each other. Dr. Owczarek hypothesizes hat depending on which cell type undergoes cancerous transformation, bladder cancer may be more or less malignant, and that this contributes to the outcome for the patient.

To investigate whether this is indeed the case, Dr. Owczarek is planning to utilize an experimental mouse model, which resembles human disease. Based on previous experimental work carried out in the laboratory in which he works, has already identified genes that cause lethal bladder cancer in the mouse model. In the research that he is now proposing, he will examine the differences between tumors that arise from different types of bladder epithelial cells, which are based on these genetic modifications. Sophisticated analysis of these tumors will allow Dr. Owczarek to find the similarities and differences of cancers that arise from different cell types in the bladder. In so doing, he will identify approaches to distinguish the type of epithelial cells from which cancers arise in the patient. Dr. Owczarek's successful implementation of these studies will help to identify appropriate and effective anticancer therapies based on cell of origin of cancer.

Dornier MedTech

[ return to top ]
Bharathi Rajaganapathy, PhD

Bharathi Rajaganapathy, PhD

Project Title: Exploring the Molecular Mechanism of Inflammatory Response in a New Rat Model of Radiation Cystitis

Institution: Beaumont Health System

Mentor: Michael Chancellor, MD

Sponsor: AUA North Central Section Research Scholar Fund

As result of radiation therapy for the treatment of pelvic cancer, there are a growing number of cancer survivors who are experiencing adverse effects of radiation therapy such as radiation cystitis. It is believed that inflammation has an important role in radiation cystitis. As such, Dr. Rajaganapathy will develop tacrolimus (well-known immunosuppressant) as a novel drug therapy to treat radiation cystitis by targeting the bladder's inflammatory mechanisms locally using intravesical bladder targeted delivery. He will utilize state of the art facilities including, Small Animal Radiation Research Platform (SARRP), Magnetic Resonance Imaging (MRI) and various molecular techniques in this study to develop a successful therapy for radiation cystitis.

AUA North Central Section Research Scholar Fund

[ return to top ]
Sungyong You, PhD

Sungyong You, PhD

Project Title: An Epigenomic Pathway From Cholesterol to Intracrine Androgen

Institution: Cedars-Sinai Medical Center

Mentor: Michael Freeman, PhD and Jayoung Kim, PhD

Sponsor: AUA Western Section Research Scholar Fund

Prostate cancer (PC) is incurable when it becomes resistant to current therapies. Dr. You and colleagues have recently discovered that a protein, scaffold attachment factor B1 (SAFB1), is a novel regulator of the androgen receptor and other proteins associated with PC progression to end-stage disease. The goal of his research project is to identify and functionally characterize the gene regulatory networks controlled by SAFB1. He will use computational, laboratory, and genomics methods to uncover this novel network. This project is directed toward elucidating the molecular mechanisms that promote lethal prostate cancer so that novel methods for combating the disease and substantially prolonging life can be found.

AUA Western Section Research Scholar Fund

[ return to top ]

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT